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with HH and azoospermia. He was treated with gon-
adotropin therapy but remained azoospermic. Testicular 
biopsy showed maturational arrest and hypospermatogen-
esis. Analysis of the NR0B1 gene showed a heterozygous 
c.836C > T substitution in exon 1, resulting in a change 
of codon 279 from proline to leucine (p.Pro279Leu). This 
change alters the structure of the repression helix domain 
of DAX-1 and affects protein complex interactions with 
NR5A family members.
Conclusions We describe two missense mutations within 
the putative carboxyl-terminal ligand binding domain of 
DAX-1, presenting with AHC and HH in adulthood, from 
a single center. DAX-1 mutations may be more frequent in 
adults than previously recognized. We recommend testing 
for DAX-1 mutations in all adults with primary AI and HH 
or impaired fertility where the etiology is unclear.
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Abbreviations
ACTH  Adrenocorticotropin hormone
AHC  Adrenal hypoplasia congenita
AI  Adrenal insufficiency
CF  Cystic fibrosis
DAX-1  Dosage sensitive sex reversal, adrenal hypo-
plasia, critical region on the X chromosome, 
gene 1
FSH  Follicle-stimulating hormone
hCG  Human chorionic gonadotropin
HH  Hypogonadotrophic hypogonadism
hMG  Human menopausal gonadotropin
GnRH  Gonadotropin releasing hormone
IU  International units
Abstract 
Purpose DAX-1 (NR0B1) is an orphan nuclear receptor, 
which plays a critical role in development and regulation 
of the adrenal gland and hypothalamo–pituitary–gonadal 
axis. Mutations in NR0B1 lead to adrenal hypoplasia con-
genita (AHC), hypogonadotropic hypogonadism (HH) and 
azoospermia in men. Presentation is typically with adre-
nal insufficiency (AI) during infancy or childhood. To date 
only eight cases/kindreds are reported to have presented in 
adulthood.
Methods We describe two new cases of men with DAX-1 
mutations who presented in adulthood and who were diag-
nosed at a large University Hospital.
Results Case 1 presented with AI at 19 years. At 38 
years he was diagnosed with HH. Detailed history revealed 
a brother diagnosed with AI at a similar age. Sequenc-
ing of the DAX-1 (NR0B1) gene revealed a heterozygous 
c.775T > C substitution in exon 1, which changes codon 
259 from serine to proline (p.Ser259Pro). Case 2 was diag-
nosed with AI at 30 years. Aged 37 years he presented 
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IVF  In-vitro fertilisation
kDA  Kilo Dalton
L  Litre
LBD  Ligand binding domain
LH  Luteinizing hormone
LRH  Liver receptor homolog-1
mmol  Millimole
nmol  Nanomole
NR0B1  Nuclear receptor subfamily 0, group B, 
member 1
NR5A1  Nuclear receptor subfamily 5, group A, 
member 1
NR5A2  Nuclear receptor subfamily 5, group A, 
member 2
pmol  Picomole
RH  Repression helix
SDS  Standard deviation scores
SF-1  Steroidogenic factor-1
SHBG  Steroid hormone binding globulin
TESE-ICSI  Testicular sperm extraction for intracytoplas-
mic sperm injection
Introduction
Primary adrenal insufficiency (AI) is a potentially life-
threatening condition that results from a number of differ-
ing etiologies including autoimmune, genetic, and develop-
mental disorders. The etiology is important for establishing 
potential associated comorbidities, inheritance, and opti-
mal management. DAX-1 (dosage sensitive sex reversal, 
adrenal hypoplasia, critical region on the X chromosome, 
gene 1) is an orphan nuclear receptor encoded by the 
NR0B1 gene. DAX-1 has a characteristic carboxyl-terminal 
ligand-binding domain (LBD) and an atypical DNA bind-
ing domain. The gene is located on the short arm of the X 
chromosome, in the Xp21 region, and plays a critical role 
in the embryological development of multiple endocrine 
tissues. It is expressed in the hypothalamus, pituitary gland, 
adrenals and gonads. After completion of tissue develop-
ment DAX-1 continues to play a role in the regulation of 
hormone production.
Clinically, mutations in DAX-1 result in the X-linked 
form of primary adrenal hypoplasia congenita (AHC), 
hypogonadotrophic hypogonadism (HH) and azoospermia 
in men [1, 2]. Classically, males present in infancy or early 
childhood, with primary adrenal failure or isolated min-
eralocorticoid deficiency, with HH becoming apparent in 
adolescence by absent or arrested pubertal development 
[3]. Females are carriers and therefore generally unaffected. 
A spectrum of clinical presentations have been described, 
including delayed onset of AI and partial HH or even tran-
sient early puberty [4, 5]. In contrast, the description of 
DAX-1 (NR0B1) gene mutations presenting with onset of 
AI and HH in adulthood are rare.
We present two men with adult-onset AI and HH, 
who were found to have DAX-1 mutations, in addition 
to reviewing the previously described cases/kindreds of 
DAX-1 mutations presenting during adulthood.
Case 1
A 42-year-old man with known cystic fibrosis (CF) and 
secondary diabetes was referred to Endocrinology for man-
agement of his Addison’s disease and androgen replace-
ment. He was diagnosed with CF aged 4 years. As a conse-
quence of CF he suffered mild abrogation of growth, with 
a final height of −2.5 SDS. His corresponding weight was 
−1.4 SDS, and pubertal development was assessed to be 
Tanner stage 5 at age 16. At age 18 years he was diagnosed 
with CF-related diabetes mellitus requiring insulin. During 
admission with a respiratory exacerbation of his CF at age 
19 years he was noted to be pigmented, with serum sodium 
124 mmol/L and potassium 5.1 mmol/L. Further tests con-
firmed cortisol insufficiency [9am cortisol <50  nmol/L 
(<1.8 µg/dL)] in association with unrecordable aldosterone 
[<55pmol/L (<1.5  ng/dL)]. Plasma renin activity is not 
available from the time of diagnosis. The patient was diag-
nosed with Addison’s disease and commenced on hydro-
cortisone and fludrocortisone replacement. At the time of 
the AI diagnosis the patient was on a regular Budesonide 
inhaler. However he was not on any oral medications (i.e. 
oral steroids or imidazoles), which could have caused iatro-
genic adrenal insufficiency.
At 35 years of age he underwent lung transplantation 
for end-stage pulmonary disease, necessitating long-term 
corticosteroid and immunosuppressive therapy with tac-
rolimus and mycophenolate mofetil. At age 38 years he 
presented with symptoms of low libido, was found to have 
HH [LH 1.6 IU/L, FSH 10.2 IU/L, testosterone 3.3 nmol/L 
(95 ng/dL), SHBG 48 nmol/L, estradiol 54pmol/L (14.7 pg/
mL)], and was commenced on testosterone replacement. At 
the time of diagnosis of HH the patient was on hydrocor-
tisone, as well as tacrolimus and mycophenolate mofetil. 
He was then lost to endocrine follow-up, however, on re-
presentation aged 42 years, a detailed history revealed he 
had a brother diagnosed with Addison’s disease at a simi-
lar age. Investigations of additional pituitary axes were 
within normal limits [TSH 1.29  miu/L (reference range 
0.2–4.0), free T4 17.9 pmol/L (reference range 10.0–20.0), 
prolactin 278  miu/L (normal level <600)], and a pituitary 
MRI was unremarkable. Neither the patient nor his brother 
have fathered children. Given the presence of Addison’s 
disease with HH, potential infertility, and family history, 
the patient was tested for mutation in the DAX-1 (NR0B1) 
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gene. DNA analysis revealed a heterozygous c.775T > C 
(p.Ser259Pro) substitution within exon 1 of the DAX 
gene, which changes codon 259 from serine to proline in 
the putative LBD (Fig. 1). The results of in silico analysis 
suggested causality. p.Ser259 is a highly conserved amino 
acid in the ligand binding domain of the nuclear hormone 
receptor core of DAX1. SIFT (http://www.blocks.fhcrc.org/
sift) predicts that p.Ser259Pro will affect protein function. 
Polyphen (http://www.genetics.bwh.harvard.edu) predicts 
p.Ser259Pro to be probably damaging. Russell analysis 
(http://www.russell.embl.de/ass) predicts the amino acid 
substitution from serine to proline to be disfavoured. Splic-
ing (Alamut) c.775T > C is predicted that the variant does 
not affect the splicing of DAX1. The patient has declined 
genetic counseling, as he has not had any family plans so 
far.
Case 2
A 30-year-old man presented with hyponatremia and 
hyperpigmentation. The presence of AI was confirmed with 
a short synacthen test (stimulation with 250 micrograms of 
synacthen), which revealed a baseline cortisol of 94 nmol/L 
(3.4 µg/dL) and a peak cortisol of 112 nmol/L (4 µg/dL). 
Serum aldosterone was <55 pmol/L (<1.5 ng/dL); however 
plasma renin activity is not available from the time of diag-
nosis. Adrenal antibodies were negative. He was diagnosed 
with Addison’s disease and commenced on hydrocortisone 
and fludrocortisone. At that time it was commented that his 
secondary sexual characteristics were normal, however, his 
testes were small. Gonadotropins showed LH 4.0 IU/L and 
FSH 10.0  IU/L, however a testosterone from that time is 
not available.
Seven years later he presented to the Urology depart-
ment with ejaculatory failure and subfertility. On examina-
tion his secondary sexual characteristics were documented 
to be consistent with androgen deficiency. He had a small 
left testis and an impalpable right testis due to a hydro-
cele. Semen analysis and post-ejaculatory urine showed 
azoospermia. His initial pituitary hormone profile revealed 
LH <0.5 IU/L, FSH 5.5 IU/L and testosterone <0.9 nmol/L 
(26  ng/dL). His remaining pituitary hormone profile was 
unremarkable [TSH 0.84 miu/L (reference range 0.2–4.0), 
free T4 13.8 pmol/L (reference range 10–20), random 
GH <0.1 mcg/L, IGF-1 36.9  nmol/L (reference range 
10.1–28.4), prolactin 77  miu/L (normal level <600)], and 
pituitary imaging revealed no abnormalities. GnRH stimu-
latory test showed peak LH and FSH of 1.0 and 8.4 IU/L 
respectively. He was commenced on hCG and hMG injec-
tions which normalised his testosterone level [22.1 nmol/L 
(636 ng/dL)], sexual function, and secondary sexual char-
acteristics, however, he remained azoospermic. He was 
referred to the Assisted Conception Unit and testicular 
sperm extraction (TESE) was attempted, but failed. His-
tological examination of his testis showed maturational 
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Fig. 1  Schematic diagram of the DAX-1 protein showing reported 
missense mutations [6]. Asterisk represent mutations associated with 
adult presentation of Adrenal Hypoplasia Congenita and Hypogon-
adotropic Hypogonadism (Modified with permission from Lin et  al. 
Copyright © 2006 by The Endocrine Society)
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arrest and hypospermatogenesis (Fig.  2). He was com-
menced on androgen replacement and continued his man-
agement under the Endocrine team. The association of AI 
and HH with poor response to fertility treatment prompted 
testing of the DAX-1 (NR0B1) gene. The test was per-
formed by direct sequencing and revealed a hemizygous 
c836C > T substitution in exon 1. This missense mutation 
occurs within a ‘hot spot’ in the putative ligand binding 
domain which changes codon 279 from proline to leucine 
(p.Pro279Leu) (Fig.  1). The mutation has not previously 
been reported on the Human Genome Mutation Data-
base and is not listed as a single nucleotide polymorphism 
(SNP) using the SNP-checker software. Investigation of 
the possible pathogenicity of this variation using Alamut 
software, as well as modelling, revealed that the sequence 
change occurs in both a highly conserved nucleotide and 
highly conserved amino acid that likely interacts  directly 
with NR5A1/SF-1 (Fig.  3). The patient has not required 
genetic counseling with regards to his DAX-1 mutation, as 
previous investigations have shown infertility. He and his 
partner have now become parents to a healthy child follow-
ing assisted conception via donor insemination.
Table 1 summarizes the endocrine investigations which 
led to the diagnosis of primary AI and HH in both our 
cases.
Discussion
We describe two unrelated men who demonstrate clinical 
presentation of X-linked adrenal hypoplasia during adult-
hood. In keeping with the majority of previous descrip-
tions, both cases presented with AI prior to HH. In our 
patients AI was diagnosed at the age of 19 and 30 years, 
with hypogonadism diagnosed at 38 and 37 years respec-
tively. Both DAX-1 mutations detected within our cases lie 
within the putative ligand binding domain (LBD).
The NR0B1 gene encodes a 51  kDa protein which 
is part of the orphan nuclear receptor superfamily. The 
amino terminus containing three LXXLL-like motifs 
is implicated in protein–protein interactions, and the 
carboxyl terminus is a classic LBD. DAX-1 regulates 
development and function of the adrenal cortex and 
hypothalamo–pituitary–gonadal axis [1, 2], primar-
ily by repression of gene expression. In part its actions 
are mediated by repression of another nuclear receptor, 
steroidogenic factor-1 (SF-1, NR5A1) [10]. Mutations 
in DAX-1/NR0B1 classically present in males during 
infancy or childhood with primary adrenal failure or less 
commonly isolated mineralocorticoid deficiency, with 
hypogonadism becoming apparent as failure to enter or 
progress through puberty [3, 11]. A further feature of 
mutations in DAX-1 is a primary defect in spermatogen-
esis [12], characterized typically by failure to respond to 
exogenous gonadotropins [11, 13]. A single birth has been 
reported after finding rare spermatozoa in a man with HH 
resulting from a DAX-1 mutation after TESE-ICSI [14]. 
In addition to the more classic presentation, isolated HH 
in a female homozygous for mutations in NR0B1 [15]; 
extreme pubertal delay in heterozygous female carriers 
[13]; 46,XY gonadal dysgenesis resulting from duplica-
tion of Xp21.2 [16]; and AHC as part of skewed X inacti-
vation [17] have been described in females. More than 80 
mutations in DAX-1 have been described, the majority of 
which are nonsense or frameshift mutations resulting in 
a truncated protein [5, 18]. Deletion of as few as the last 
Fig. 2  Histology obtained from testicular biopsy of patient with 
hemizygous c836C > T substitution in exon 1 of the DAX1 (NR0B1) 
gene. This missense mutation occurs within a ‘hot spot’ in the puta-
tive ligand binding domain which changes codon 279 from proline to 
leucine (p.Pro279Leu); a Demonstrates maturational arrest of sper-
matogenesis. The tubules contain germ cells but in low numbers. 
There is maturation up to primary spermatids but absent spermata-
zoa; b Demonstrates hyalinised and atrophic tubules (Sertoli cells 
only). Leydig cells are observed between the tubules. They are more 
easily seen compared to normal testis because of the general paucity 
of tubules (pseudohyperplasia)
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nine amino acids of the DAX-1 protein, constituting the 
putative activation function-2 domain, is associated with 
a severe clinical phenotype [19]. Less common are mis-
sense mutations which predominantly cluster within the 
putative carboxyl LBD [11, 20]. Considerable variability 
in presentation, even within affected family members, is 
described, relating primarily to timing of presentation 
of adrenal insufficiency [1, 21, 22], although there is a 
suggestion that younger brothers are diagnosed earlier, 
likely representing increased awareness [23].
To date we are aware of only eight other reports of 
DAX-1 mutations in cases/kindreds presenting in adult-
hood (Table 2) [22, 24–29]. Three of these are associated 
with amino-terminal nonsense changes in DAX-1, and five 
are associated with carboxyl-terminal missense mutations. 
Table 2 summarizes the clinical cases of adult-onset adrenal 
Fig. 3  Model of the effect of the p.Pro279Leu mutation on the DAX-
1:LRH-1 complex. The proline at 279 (shown in white, left panel) 
flanks the core repression helix domain of DAX-1 (magenta). The 
change to leucine (shown in white, right panel) likely increases the 
flexibility of the loop and produces a small displacement of an argi-
nine side chain in LRH-1 (cyan). The comparative modelling of the 
human DAX-1: LHR-1 (Uniprot codes P51483 and O00482) com-
plex was performed using the MODELLER program [7], as imple-
mented in the Build Homology Model module of Discovery Studio 
v2.1 software (Accelrys Inc., San Diego, USA). The crystal structure 
of murine DAX-1:LHR-1 complex (PDBid 3F5C) solved at 3.0  Å 
resolution was used as template [8]. The protein complexes for the 
wild type and DAX-1 p.Pro279Leu mutant were modelled as (DAX-
1)2:LHR-1 trimers, following the crystal structure oligomerization 
state. The resultant models were energy minimized using the con-
jugate gradient algorithm with the CHARMM22 force field until a 
RMS gradient of 0.001 kcal/molÅ was reached; a dielectric constant 
of 80 and a distance-dependent dielectric model was used during 
minimization [9]
Table 1  Summary of the 
endocrine investigations 
performed in the two adult 
cases of DAX-1 (NR0B1) gene 
mutations (n/a not available)
Test Case 1 Case 2 Reference range
9am Cortisol (nmol/L) <50 Not performed 150–600
Short Synachten Test (nmol/L) Not performed 94 (cortisol at 0 min)
112 (cortisol at 30 min)
Corti-
sol >500 nmol/L 
at 30 min
Aldosterone (pmol/L) <55 <55 150–850
Plasma renin activity (nmol/L/h) n/a n/a 0.5–3.5
Testosterone (nmol/L) 3.3 <0.9 8.0–30.0
LH (IU/L) 1.6 <0.5 1.0–9.0
FSH (IU/L) 10.2 5.5 1.0–9.0
SHBG (nmol/L) 48 n/a 13–71
Prolactin (miu/L) 278 77 <600
TSH (miu/L) 1.2 0.84 0.2–4.0
Free T4 (pmol/L) 17.9 13.8 10–20
GH (mcg/L) n/a <0.1 –
IGF-1 (nmol/L) n/a 36.9 10.1–28.4
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insufficiency and hypogonadotrophic hypogonadism asso-
ciated with mutations of the DAX1 (NR0B1) gene. Most of 
these patients presented with AI; however in two cases HH 
was the initial presentation, with the diagnosis of AI occur-
ring at a later stage following further endocrine investiga-
tions. A recent case report described the same p.Ser259Pro 
mutation, as we found, in two Korean brothers who pre-
sented with primary AI at the age of 28 and 36 years 
respectively without evidence of hypogonadism [29]. The 
mutant protein showed reduced expression and impaired 
DAX-1 function in an in  vitro assay. Clearly, these men 
will need follow-up, as hypogonadism may occur several 
years later, based on our experience.
To date, the described mutations within DAX-1 kin-
dreds which have at least one case presenting in adult life 
include p.Q37X, p.W39X in two kindreds, p.S259P in 
three patients, p.P279L, p.Gln305Hisfs*67 (c.915delG), 
p.Y380D, and p.I439S (Table  2). The first two of these 
mutations result in a functional DAX-1 protein from an 
in-frame translational site downstream to the premature 
stop codon [24–26]. The next four of the described muta-
tions are missense mutations widely distributed throughout 
the carboxyl LBD, but that may form important structural 
components of the protein structure or affect subcellular 
localisation [27, 28]. The final described mutation was a 
frameshift within the LBD [22].
Our patients add to previous reports of late-onset 
X-linked AHC presenting in adulthood, and expand the 
list of DAX-1 mutations that can present in this way. The 
p.Pro279Leu mutation is a novel missense mutation within 
the LBD, which to our knowledge has not been previously 
reported in the literature. Based on the crystal structure of 
DAX-1 bound to NR5A2/LRH-1, this codon is one of two 
highly conserved proline residues flanking a unique repres-
sion helix (RH) domain that interacts directly with NR5A2 
(Fig.  3) [8]. The core of this RH domain is a variant 
“LXXLL” motif containing exposed hydrophobic residues 
(Human sequence: 273_279PCFQVLP; Mouse sequence: 
275_281PCFQILP). This region of DAX-1 blocks the 
interaction of co-activator with NR5A2, resulting in tran-
scriptional repression. The proline at 279 flanks the core 
region. The change to leucine increases the flexibility of 
the loop and produces a small displacement of an arginine 
side chain in LRH-1. This change causes partial disruption 
of the protein–protein interaction and a delayed-onset phe-
notype. Of note, p.Leu278Arg and p.Leu278Pro variants 
affecting the core leucine have been reported in patients 
with classic early-onset X-linked adrenal hypoplasia.
The p.Ser259Pro mutation, which is the most amino-
terminal mutation described in the putative LBD to date 
(Fig.  1), has also been recently reported in two Korean 
brothers with late-onset primary AI and no evidence of 
hypogonadism [29]. The authors demonstrated that the 
mutation caused a loss of the NR0B1 gene function, as 
proven by the lower NR0B1 protein levels in cells with 
NR0B1 mutation (measured by western blot) compared 
with wild type cells [29]. The vast majority of missense 
mutations are reported to occur in the putative carboxyl 
terminal LBD, specifically within two clusters between 
codons 262–300 and 361–385, with a scattering of fur-
ther missense mutations immediately adjacent to the car-
boxyl terminus [5]. Both the mutations we describe fall 
around the first of these “hotspots”.
Genetic analyses in our patients were performed by 
bi-directional sequencing of exons 1 and 2 of NR0B1. A 
limitation to our case reports is that the results of some 
endocrine investigations are not available for our patients, 
including the values of the ACTH and plasma renin activ-
ity at the time of diagnosis of primary AI. This is because 
in both cases, the initial diagnosis of primary AI was 
made approximately 20 years prior to the genetic confir-
mation of the mutation in the DAX-1 gene and therefore 
some historic medical data is no longer available in the 
patients’ hospital records.
Adult presentation of patients with DAX-1 mutations 
likely reflects partial, rather than complete loss of repres-
sor activity, as demonstrated in transient gene expression 
studies and from structural predictions [24, 27, 28]. The 
finding of two unrelated cases within our center, where 
we follow-up approximately 40–50 cases of primary AI, 
suggests presentation of DAX-1 during adulthood may be 
under-recognized. This hypothesis was investigated in a 
cohort of 29 male and female patients with adult-onset 
AI where common causes including autoimmune disease, 
steroidogenic defects, and metabolic disorders (e.g. adre-
noleukodystrophy) had been excluded. Within this cohort 
no patients were found to have a DAX-1 mutation [6]. 
However, none of these patients were reported to have 
concurrent hypogonadism. The current report strongly 
suggests that the combination of primary AI with HH at 
any age should raise the suspicion of DAX-1 gene muta-
tion, and prompt genetic testing. Diagnosing X-linked 
AHC is clinically important for identifying siblings who 
could be at risk of life-threatening AI [26], identifying 
sisters who might have affected sons, and optimising 
approaches to endocrine replacement and fertility treat-
ment. As the hypogonadism can occur some time after 
the diagnosis of adrenal insufficiency, awareness of this 
condition, careful monitoring, and possibly, genetic test-
ing is warranted.
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